This account is no longer active or monitored. For updates about ACS Chemical Neuroscience, follow @ACSPublications and @ACSBioMed.
Washington, DC
Joined August 2009
- Tweets2.1K
- Following643
- Followers3.7K
- Likes542
Pinned Tweet
This account will no longer be active or monitored.
We welcome our community to follow @ACSPublications or sign up for e-Alerts for future updates from ACS Chemical Neuroscience: go.acs.org/cbL
Don't miss out on this exciting discussion!
This collection from #ACSChemNeuro dives into the research around #MDMA as a potential breakthrough therapy
Read the latest research ➡ go.acs.org/bMR
ACSChemNeurosci retweeted
Next week is World #AntimicrobialResistance Awareness Week! Join us for a webinar discussing the cutting edge work being done to fight multi-drug resistant bacteria. 🦠
📅 Wed Nov 20, 11am EST.
Register here ➡️ go.acs.org/bF7
ALT Free Live Webinar Wednesday, November 20th, 2024, 11 am-12:30 pm EST New Targets, New Tools: Advancing the Fight Against Antimicrobial Resistance Co-produced with ACS Publications
ACSChemNeurosci retweeted
Check out our recent works on Chronic pain published @ACSChemNeurosci
A great collaboration between @DarrenDerksen lab and @zymedyne
Many thanks to @MitacsCanada for the funding!
This quoted post is unavailable.
Don't miss out on this exciting discussion!
This collection from #ACSChemNeuro dives into the research around #MDMA as a potential breakthrough therapy
Read the latest research ➡ go.acs.org/auk
Curious about the latest research on MDMA treatments? Check out our recent collection of articles on the subject ➡ go.acs.org/arI
The psychedelic treatment, for PTSD, was rejected last week by government regulators. nyti.ms/3YJoO4i
ACSChemNeurosci retweeted
❗ LAST CALL! Call for Papers: ACS Pharmacology and Translational Science invites submissions for a Virtual Special Issue on new perspectives and advances in translational #pain research to treat pain.
Submit papers by August 1, 2024 ➡ go.acs.org/ajc
ACSChemNeurosci retweeted
I am proud to have collaborated with @cahhcardi et al in this amazing paper now published in @ACSChemNeurosci.
Link: pubs.acs.org/doi/10.1021/acs…
@Ariel_Lab
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy
Read the latest research ➡ go.acs.org/a9I
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy
Read the latest research ➡ go.acs.org/9Ze
ACSChemNeurosci retweeted
Read our latest review on the gut-microbiome brain axis in Parkinson’s disease and role of “biotics” approach #neuroscience #gutmicrobiota @ACSChemNeurosci pubs.acs.org/doi/10.1021/acs…
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy
Read the latest research ➡ go.acs.org/9Mn
ACSChemNeurosci retweeted
#research
Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition (Friedecký, @konvalinka_jan) - @ACSChemNeurosci: doi.org/10.1021/acschemneuro…
@FriedeckyGroup @IOCBPrague @CzechAcademy @UPOlomouc
ACSChemNeurosci retweeted
To sum up today's adcomm: While the experts saw potential in the use of MDMA-assisted therapy in the treatment of PTSD, there were too many confounding variables and possible safety concerns to push for approval #Lykos
FDA Advisory Committee votes against recommending Lykos' #MDMA treatment for PTSD
Read our latest MDMA research here ➡ go.acs.org/9Er
Fascinating discussions online today surrounding the FDA's consideration of a new #MDMA treatment for PTSD 🤔
When is a double-blinded study not enough? How can you blind for a treatment that includes such pronounced and well-known effects?
Let us know what you think! ⬇
📢New collection of #ACSChemNeuro research as the FDA is expected to announce a decision on a new treatment involving #MDMA today ⏰
Read the latest research ➡ go.acs.org/9Er
ACSChemNeurosci retweeted
It's all things adamantane in our (@Lambert_Usyd) latest synthetic cannabinoid work, out now in @ACSChemNeurosci!
We synthesised and evaluated a library of adamantane-derived SCRAs, including fluorinated and deuterated analogues 🧪
🧵
pubs.acs.org/doi/10.1021/acs…
ACSChemNeurosci retweeted
This study builds on our @ACSChemNeurosci paper last year, where @PashaDavoudian mapped c-Fos response in the brain after psilocybin or ketamine, identifying the list of shared and distinct brain regions impacted by the drugs
pubs.acs.org/doi/10.1021/acs…
